Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cambridge, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV

Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC

2863

Studies in scope

industry-sponsored, all four open statuses

1385

Recruiting now

open to new participants

542

Lead sponsors

across recruiting studies

Top sites

London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425

Trials with a site in Cambridge

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Not yet open

First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant

NCT07032038Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy

Rinri Therapeutics

Phase 1/2

Birmingham, Cambridge, London

2027-09

Not yet open

Early Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults

NCT07841457Probiotic Intervention, Healthy Adult Participants

OneCarbon

Not applicable

Cambridge

2027-01-01

Not yet open

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

2,380

Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford

2026-12-16

Not yet open

Evaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes

NCT07401901Type 1 Diabetes (T1D)

Medtronic MiniMed, Inc.

Not applicable

230

Cambridge, Leicester, Manchester

2026-10-15

Recruiting

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189Oropharyngeal Carcinoma (OPC)

DrugsCRB-701·Cetuximab·Docetaxel

Corbus Pharmaceuticals Inc.

Phase 3

260

London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham

2026-09-29

Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450Multiple Myeloma

DrugsRamantamig·Bortezomib·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,000

Blackpool, Cambridge, Canterbury

2026-09-09

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance

2026-09-08

Recruiting

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Epitopea Ltd

Phase 1

Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton

2026-09

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield

2026-08-31

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Cambridge, London

2026-08-25

Recruiting

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

NCT07686263Schizophrenia

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

472

Cambridge

2026-08-20

Recruiting

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants

NCT07789899Pulmonary Disease, Chronic Obstructive

DrugGSK3862995B

GlaxoSmithKline

Phase 1

Cambridge

2026-08-18

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford

2026-08-05

Recruiting

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284High-risk Muscle Invasive Urothelial Carcinoma

DrugsEnfortumab Vedotin·Rilvegostomig·Dato-DXd·Opdivo

AstraZeneca

Phase 3

915

Bristol, Cambridge, Preston, Sheffield

2026-07-16

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Cambridge, Edinburgh, Manchester

2026-07-10

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield

2026-05-20

Recruiting

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832Acute Myeloid Leukemia

DrugPivekimab Sunirine

AbbVie

Phase 1

Cambridge

2026-05-20

Recruiting

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

NCT07427394Advanced Breast Cancer

DrugsAtirmociclib·Camizestrant

AstraZeneca

Phase 2

Cambridge, London, Manchester

2026-05-06

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Cambridge, London

2026-04-23

Recruiting

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332Pulmonary Arterial Hypertension

Inhibikase Therapeutics

Phase 3

486

Cambridge, Glasgow, London

2026-04-23

Recruiting

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995Metastatic Castration-resistant Prostate Cancer

DrugsBNT324·Prednisone/Prednisolone·Docetaxel

BioNTech SE

Phase 3

736

Cambridge, London, Sutton

2026-04-22

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181Systemic Lupus Erythematosus

DrugBI 3000202

Boehringer Ingelheim

Phase 2

405

Basingstoke, Belfast, Cambridge, Doncaster, London

2026-04-20

Recruiting

Visugromab in Cachexia International Trial

NCT07112196Cancer-associated Cachexia

DrugsVisugromab·Visugromab RDE

CatalYm GmbH

Phase 2/3

518

Brighton, Cambridge, Dundee, Edinburgh, Guildford, Manchester, Newcastle upon Tyne

2026-04-16

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

NCT07158242Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

100

Birmingham, Cambridge, Sheffield

2026-04-15

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton

2026-04-09

Recruiting

A Gaucher Disease Gene Therapy Trial With FLT201

NCT07223944Gaucher Disease Type 1

Spur Therapeutics

Phase 3

Birmingham, Salford, London, Cambridge

2026-04-07

Recruiting

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE

ADARx Pharmaceuticals, Inc.

Phase 3

Cambridge, Cardiff, London, Southampton

2026-04-02

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351Advanced Renal Cell Carcinoma (RCC)

DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy

Bristol-Myers Squibb

Phase 1/2

474

London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey

2026-03-26

Recruiting

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709Huntington Disease

DrugVotoplam

Novartis Pharmaceuticals

Phase 3

770

Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford

2026-03-24

Recruiting

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183Colitis Ulcerative, Ulcerative Colitis

Merck Sharp & Dohme LLC

Phase 2

100

Cambridge, Bury, London, Huddersfield

2026-03-24

Recruiting

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors

NCT07438782Neoplasms

GlaxoSmithKline

Phase 1

Cambridge, Edinburgh

2026-03-23

Recruiting

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855Solid Tumours

DrugSaruparib

AstraZeneca

Phase 1/2

180

Cambridge, London, Sutton

2026-03-17

Recruiting

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

NCT07431112Alpha 1 Antitrypsin Deficiency

AIRNA Corporation

Phase 1

Cambridge, London, Southampton

2026-03-17

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool

2026-03-16

Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510Non-Small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Pembrolizumab

Bristol-Myers Squibb

Phase 3

750

Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London

2026-03-12

Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

DrugsCetuximab·Nab-paclitaxel·Gemcitabine

Revolution Medicines, Inc.

Phase 3

900

Torquay, Birmingham, Cambridge, Liverpool, London, Manchester

2026-03-09

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent

2026-03-05

Recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398Pulmonary Hypertension Associated With HFpEF

DrugTNX-103

Tenax Therapeutics, Inc.

Phase 3

540

Cambridge, Glasgow, London, Sheffield, Swindon

2026-03-03

Recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma

DrugsLevofolinate·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Global Development, Inc.

Phase 3

614

Cambridge, Cottingham, Ipswich, London, Maidstone, Sutton

2026-02-17

Recruiting

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558Ovarian Neoplasms, Ovarian Cancer

DrugsMvasi·Sacituzumab tirumotecan·Avastin·Bevacizumab

Merck Sharp & Dohme LLC

Phase 3

900

Cambridge, Leicester, London, Manchester

2026-02-16

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Bebington, Bradford, Cambridge, Carshalton, Leicester, London, Middlesbrough, Salford

2026-02-16

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton

2026-02-05

Recruiting

Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty

NCT07214311Prosthetic-joint Infection

Peptilogics

Phase 2/3

240

Cambridge, Edinburgh, Norwich, Leeds

2026-02-03

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Cambridge, Dundee, Leeds, London, Manchester, Oxford

2026-02-03

Active, closed

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT07336446Prostate Cancer

DrugSaruparib

AstraZeneca

Phase 1/2

Cambridge

2026-01-27

Recruiting

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

NCT07230288Idiopathic Pulmonary Fibrosis

AbbVie

Phase 2

165

Cambridge, Edinburgh, London, Southampton, Norwich

2026-01-23

Recruiting

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

NCT07053800Lupus Nephritis

DrugObecabtagene autoleucel

Autolus Limited

Phase 2

Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester

2026-01-16

Recruiting

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

NCT07266402Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

240

Cambridge, Glasgow, Manchester

2026-01-15

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton

2026-01-12

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London

2025-12-29

Recruiting

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

NCT06717295Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers

Javier Toledo

Observational

6,000

Cambridge, London

2025-12-20

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

NCT07287982Spinal Muscular Atrophy (SMA)

DrugARGX-119

argenx

Phase 2

Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds

2025-12-19

Recruiting

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

NCT07062588Osteogenesis Imperfecta (OI)

DrugAGA2115

Angitia Incorporated Limited

Phase 2

Cambridge, Edinburgh, London, Oxford

2025-12-12

Recruiting

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213Clostridioides Difficile Infection

AstraZeneca

Phase 2

230

Birmingham, Cambridge, Cardiff, Newcastle

2025-12-10

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

DrugCYB003

Cybin IRL Limited

Phase 3

330

Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield

2025-12-10

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton

2025-12-09

Recruiting

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

NCT07224373Multiple Sclerosis

AstraZeneca

Phase 1

Cambridge, London

2025-12-09

Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab

Janssen Research & Development, LLC

Phase 3

500

Cambridge, Cottingham, Edinburgh, Greater London, Guildford, London, Metropolitan Borough of Wirral, Northwood

2025-12-03

Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT07218926Gastrointestinal Neoplasms

DrugsIDRX-42·Sunitinib

GlaxoSmithKline

Phase 3

450

Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield

2025-12-03

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford

2025-12-02

Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146Small-cell Lung Cancer

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 3

480

Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton

2025-11-30

Recruiting

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Alexion Pharmaceuticals, Inc.

Phase 2

Birmingham, Cambridge, Leicester, London, Manchester

2025-11-26

Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402Renal Cell Carcinoma

DrugsZanzalintinib·Belzutifan·Cabozantinib

Merck Sharp & Dohme LLC

Phase 3

904

Cambridge

2025-11-26

Recruiting

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

NCT07187531Type 1 Diabetes

SAb Biotherapeutics, Inc.

Phase 2

159

Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford

2025-11-25

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Leeds, Bristol, Cambridge, Glasgow, North Finchley

2025-11-25

Active, closed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

NCT07246941Huntington's Disease

Hoffmann-La Roche

Phase 1

Cambridge

2025-11-19

By invitation

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)

NCT07156578Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc.

Phase 2

Birmingham, Cambridge, London

2025-11-10

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Belfast, Birmingham, Brighton, Cambridge, Dundee, Edinburgh, Exeter, Liverpool

2025-11-06

Recruiting

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth

2025-10-16

Recruiting

A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission

NCT07156175Microscopic Colitis

Sanofi

Phase 2

Cambridge, Oxford

2025-10-14

Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722Crohn Disease

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 2/3

1,092

Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport

2025-10-03

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Cambridge, London, Edinburgh, Liverpool

2025-10-03

Active, closed

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)

DrugNeflamapimod

EIP Pharma Inc

Phase 2

Cambridge, Newcastle upon Tyne

2025-10-02

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Cambridge, London, Plymouth, Sutton

2025-10-01

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport

2025-10-01

By invitation

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

NCT07204938Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

145

Bristol, Cambridge, Frimley, Hampstead, London, Plymouth

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Cottingham, Cambridge, London, Norwich, Rochdale

2025-10-01

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Cambridge, Manchester

2025-09-30

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336Ulcerative Colitis

Genentech, Inc.

Phase 2

224

London, Liverpool, Oxford, Cambridge

2025-09-29

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

Ashburton, Belfast, Bellshill, Birmingham, Bristol, Bury St Edmunds, Cambridge, Cardiff

2025-09-22

Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787Primary Membranous Nephropathy

Alexion Pharmaceuticals, Inc.

Phase 2

Cambridge, Leicester, London, Salford

2025-09-19

Recruiting

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

NCT07176689Desmoid Tumor, Aggressive Fibromatosis

DrugNirogacestat

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 4

Cambridge, London, Manchester

2025-09-17

Recruiting

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma

DrugsCasdatifan·Cabozantinib

Arcus Biosciences, Inc.

Phase 3

720

Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne

2025-09-08

Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2

ADARx Pharmaceuticals, Inc.

Phase 3

Guildford, Cambridge, Cardiff, London, Southampton

2025-08-28

Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine

BeOne Medicines

Phase 3

351

Cambridge, Dundee, Metropolitan Borough of Wirral

2025-08-27

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Cambridge, Cardiff, Dundee, London

2025-08-07

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading

2025-08-06

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford

2025-08-06

Recruiting

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

NCT07139743Progressive Multiple Sclerosis

DrugObecabtagene autoleucel

Autolus Limited

Phase 1

Cambridge, Edinburgh, London, Sheffield

2025-08-04

Active, closed

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

NCT07022457Metastatic Melanoma, BRAF V600 Mutation Positive

DrugsBinimetinib·Encorafenib

Pierre Fabre Ltd

Observational

Westcliff-on-Sea, Birmingham, Cambridge, Coventry, London, Preston, Southampton

2025-07-31

Recruiting

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519Ulcerative Colitis

DrugRisankizumab

AbbVie

Phase 3

120

Cambridge, Sheffield, Liverpool

2025-07-28

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Birmingham, Blackpool, Bristol, Cambridge, Chester, Coventry, Dudley, Dundee

2025-07-25

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Cambridge, Bathgate, Rickmansworth, Maidstone, Taunton, Cottingham, Glasgow, Leeds

2025-07-24

Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280Hereditary Angioedemas

CSL Behring

Observational

200

Cambridge, London, Manchester, Cardiff, Frimley, Birmingham, Leeds

2025-07-21

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

Cambridge, Guildford, Hampstead, London, Maidstone, Manchester, Nottingham

2025-07-17

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

NCT07011745Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford

2025-07-16

Recruiting

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis

DrugsUplizna·Inebilizumab·Blinatumomab

Amgen

Phase 2

220

Cambridge, Edinburgh, Leicester, Newcastle upon Tyne

2025-07-16

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

Cambridge, London

2025-07-03

Not yet open

GyroGlove Use in Essential Tremor Patients

NCT05958030Essential Tremor

GyroGear Ltd

Not applicable

Cambridge, Newcastle, Oxford

2025-07

Active, closed

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

NCT06979531Primary Sjögren's Syndrome

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

180

Cambridge, Liverpool, London, Swindon, Truro

2025-06-30

Active, closed

Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options

NCT06794554Chronic Pulmonary Aspergillosis

Mundipharma Research Limited

Phase 2

Cambridge, Derby, Dundee, Edinburgh, Leeds, London, Manchester

2025-06-30

Recruiting

Bladder EpiCheck European Haematuria Study

NCT06818136Hematuria, Cystoscopy, Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter

Nucleix Ltd.

Observational

800

Dunfermline, Cambridge, Edinburgh, London, Surrey Quays

2025-06-20

Recruiting

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

NCT06850623Locally Advanced Pancreatic Adenocarcinoma

DrugModified FOLFIRINOX

EXACT Therapeutics AS

Phase 2

Cambridge, Hammersmith, Sutton

2025-06-19

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Brighton, Bristol, Cambridge, Cottingham, Coventry, Edinburgh, Exeter, London

2025-06-10

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Belfast, Birmingham, Blackpool, Bradford, Bristol, Cambridge, Cardiff, Dundee, Scotland

2025-06-09

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Birmingham, Bournemouth, Bridgend, Bristol, Calow, Cambridge, Cardiff, Chippenham

2025-06-04

Recruiting

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Bury, Cambridge, London

2025-06-03

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Cambridge, Exeter, London

2025-05-28

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

East Sussex, Cambridge, Glasgow, London, Edinburgh, Leicester, Maidstone, Manchester

2025-05-22

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Bradford, Cambridge, Manchester, London, Crumpsall, Wakefield

2025-05-20

Recruiting

Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients

NCT06861361Symptomatic Severe Aortic Stenosis

Ceric Sàrl

Not applicable

1,180

Belfast, Brighton, Cambridge, Cottingham, Coventry, London, Newcastle upon Tyne, Sheffield

2025-05-15

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon

2025-05-13

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Cambridge, London, Glasgow

2025-05-12

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Cambridge, Leeds, London, Manchester

2025-05-06

Active, closed

FARAPULSE Workflow Assessment Registry

NCT06656884Atrial Fibrillation (AF)

Boston Scientific Corporation

Observational

524

Bournemouth, Cambridge, Leicester, Newcastle upon Tyne, Southampton

2025-05-06

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Aberdeen, Rhyl, Leicester, Lincoln, High Heaton, Sunderland, Birmingham, Cambridge

2025-05-06

Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06967805Idiopathic Pulmonary Fibrosis

Mediar Therapeutics

Phase 2

164

Birmingham, Cambridge, Edinburgh, Oxford

2025-05-05

Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer

DrugPumitamig

BioNTech SE

Phase 1/2

380

Cambridge, Cardiff, Leeds, London, Manchester, Sutton

2025-04-23

Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

340

Cottingham, Oxford, Birmingham, Cambridge, Leicester, London

2025-04-17

Recruiting

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

NCT06846554Pulmonary Arterial Hypertension

Apollo Therapeutics Ltd

Phase 2

London, Bath, Cambridge, Clydebank, Sheffield

2025-04-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

DrugsSteroid mouthwash (dexamethasone·Mvasi·Acetaminophen·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

770

Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool

2025-04-09

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Bath, Cambridge, Leeds, London, Manchester, Northwood, Taunton

2025-03-27

Active, closed

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823Hereditary Angioedema (HAE)

DrugNavenibart

Astria Therapeutics, Inc.

Phase 3

157

Plymouth, Hampstead, Bristol, Cambridge, Frimley, London

2025-03-20

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Cambridge, London, Manchester, Oxford, Sheffield

2025-03-19

Active, closed

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

NCT06673056Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)

DrugN-Acetyl-L-Leucine

IntraBio Inc

Phase 3

Cambridge, Nottingham

2025-03-18

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham

2025-03-17

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290ANCA Associated Vasculitis (AAV)

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

126

Cambridge, Glasgow, London, Manchester

2025-03-13

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield

2025-03-12

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Cambridge, London, Manchester, Metropolitan Borough of Wirral

2025-03-12

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Cambridge, Coventry, Dundee, London, Manchester, Sutton

2025-03-01

Recruiting

Tensi+ European Registry

NCT07205445Overactive Bladder

Stimuli Technology

Observational

500

Bristol, Cambridge, London

2025-02-27

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Cambridge, London

2025-02-17

Active, closed

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

NCT06780449Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

400

Bristol, Cambridge, Coventry, Liverpool, London, Swansea, Taunton

2025-02-10

Recruiting

A Study to Understand How Cardiac Surgery-associated Acute Kidney Injury Develops in Participants Who Undergo Heart Surgery With the Use of Heart-lung Machine

NCT06772025Cardiac Surgery-associated Acute Kidney Injury

Bayer

Not applicable

200

Cambridge, Harefield, London

2025-02-03

Active, closed

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

NCT06812325Thyroid Eye Disease (TED)

DrugVRDN-003

Viridian Therapeutics, Inc.

Phase 3

320

Bristol, Cambridge, London, Newcastle

2025-02-03

Recruiting

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

NCT06556563Glioblastoma

DrugsTemozolomide·Keytruda·Pembrolizumab

NovoCure GmbH

Phase 3

741

London, Northwood, Birmingham, Cambridge, Cardiff, Edinburgh, Liverpool, Manchester

2025-02-03

By invitation

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

170

Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth

2025-02-01

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Aberdeen, Birmingham, Cambridge, Glasgow, Leeds, Liverpool, London, Manchester

2025-01-28

Active, closed

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420Hereditary Angioedema

Intellia Therapeutics

Phase 3

Cambridge

2025-01-15

Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126Melanoma, Cutaneous Malignant

DrugsAnzu-cel·Lifileucel·Temodar·Dacarbazine

Immatics US, Inc.

Phase 3

360

Cambridge, Glasgow, London, Manchester, Oxford, Southampton

2025-01-14

Active, closed

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Janssen Research & Development, LLC

Phase 1

Cambridge, London, Manchester

2025-01-14

Active, closed

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

NCT06619509Solid Tumours

Boehringer Ingelheim

Phase 2

Cambridge, London

2024-12-30

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield

2024-12-17

Active, closed

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

NCT06681324Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

Birmingham, Cambridge, London

2024-12-11

Active, closed

A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

NCT06734234Kidney Disease

DrugGSK4771261

GlaxoSmithKline

Phase 1

Cambridge, Exeter, London, Newcastle upon Tyne

2024-12-11

Active, closed

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969Sjogrens Syndrome

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

655

Cambridge, Doncaster, Greater London, Leeds, Liverpool, London, Peterborough, Swindon

2024-12-04

Active, closed

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Hereditary Angioedema (HAE)

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 3

London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth

2024-12-01

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne

2024-11-27

Active, closed

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

NCT06444113Multiple Sclerosis

Novartis Pharmaceuticals

Phase 4

Cambridge, London, Oxford, Salford

2024-11-25

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne

2024-11-18

Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

NCT06672549Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

125

Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool

2024-11-18

Active, closed

A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

NCT06681181Colitis, Ulcerative

GlaxoSmithKline

Phase 1

Cambridge

2024-11-18

Active, closed

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease

DrugTaladegib

Endeavor Biomedicines, Inc.

Phase 2

213

Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry

2024-11-15

Active, closed

A Study of Mosliciguat in PH-ILD

NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases

DrugMosliciguat

Pulmovant, Inc.

Phase 2

135

Cambridge, London, Clydebank

2024-10-29

Recruiting

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension

Novartis Pharmaceuticals

Phase 1/2

232

Sheffield, Cambridge, London

2024-10-24

Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Irinotecan

Janssen Research & Development, LLC

Phase 3

1,000

Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton

2024-10-18

Active, closed

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

NCT06637371Asthma

DrugAMG 691

Amgen

Phase 1

Cambridge, London, Manchester

2024-10-16

Recruiting

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

NCT06585449Huntington's Disease

Alnylam Pharmaceuticals

Phase 1

Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth

2024-10-14

Active, closed

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT06388564Chronic Graft-versus-host-disease

DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone

Incyte Corporation

Phase 2

130

Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool

2024-10-11

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

Birmingham, Cambridge, Glasgow, Leicester, London, Manchester, Middlesbrough

2024-10-04

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

NCT06609239Asthma

DrugLunsekimig

Sanofi

Phase 2

900

Cambridge, Glasgow, Bradford, Chertsey, London

2024-09-30

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Bristol, Cambridge, Glasgow Strathclyde, Leeds West Yorkshire, Liverpool, London, Middlesbrough, Plymouth

2024-09-27

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton

2024-09-25

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Cambridge, Cottingham, Glasgow, Leeds, London, Nottingham, Sutton, Torquay

2024-09-23

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Cambridge, Liverpool, London

2024-09-17

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

Dundee, Glasgow, Birmingham, Belfast, Cambridge, Edinburgh, Liverpool, London

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

Glasgow, Birmingham, Cambridge, London

2024-09-11

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Cambridge, Clydebank, London, Newcastle, Sheffield

2024-09-03

Recruiting

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271Systemic Lupus Erythematosus

DrugBelimumab

GlaxoSmithKline

Phase 1

142

Cambridge, Liverpool, London, Middlesex

2024-09-02

Active, closed

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142Immunoglobulin A Nephropathy

DrugPovetacicept

Alpine Immune Sciences Inc, A Subsidiary of Vertex

Phase 3

605

Belfast, Birmingham, Bristol, Cambridge, Glasgow, Gloucester, Leicester, London

2024-08-30

Active, closed

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391Melanoma

DrugsVancomycin·Keytruda·Pembrolizumab

Microbiotica Ltd

Phase 1

Brighton, Cambridge, Glasgow, London, Manchester, Newcastle, Sutton

2024-08-28

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Birmingham, Cambridge, Leeds, Leicester, London, Northwood

2024-08-28

Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis

DrugsKYV-101·Fludarabine·Cyclophosphamide

Kyverna Therapeutics

Phase 2/3

Cambridge, London

2024-08-28

Recruiting

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)

DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin

AstraZeneca

Phase 2

257

Cambridge, Glasgow, Manchester

2024-08-22

Recruiting

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

NCT06096116Acquired Antithrombin Deficiency

Octapharma

Phase 3

120

Cambridge, Coventry, Middlesbrough

2024-08-21

Recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

110

Cambridge, Sheffield, London, Norwich, Edinburgh

2024-08-08

Active, closed

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

DrugsIptacopan·Rituximab

Novartis Pharmaceuticals

Phase 2

Cambridge

2024-08-05

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro

2024-08-01

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Bebington, Guildford, Aberdeen, Birmingham, Bristol, Cambridge, Glasgow, Liverpool

2024-07-31

Active, closed

Long-term Extension of GTX-102 in Angelman Syndrome

NCT06415344Angelman Syndrome

DrugApazunersen

Ultragenyx Pharmaceutical Inc

Phase 3

255

Cambridge, London, Oxford

2024-07-31

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

Cambridge, London, Newcastle, Southampton

2024-07-23

Active, closed

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

NCT06405633Alpha-1 Antitrypsin Deficiency

Wave Life Sciences USA, Inc.

Phase 1/2

Birmingham, Cambridge, London

2024-07-19

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley

2024-07-19

Active, closed

HF-TRACK: A UK RCT of an Passive Heart Failure Monitoring and Tracking Device

NCT06334822Heart Failure

Heartfelt Technologies

Not applicable

186

Brough, Hull, Croydon, Bury St Edmunds, Horley, Keighley, Cambridge, London

2024-07-11

Recruiting

Hydra Registry - UK

NCT06507579Aortic Valve Stenosis

Sahajanand Medical Technologies Limited

Observational

250

Sheffield, Belfast, Cambridge, Cottingham

2024-07-11

Recruiting

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594Solid Tumors, Neoplasms

DrugMocertatug rezetecan

GlaxoSmithKline

Phase 1

675

Cambridge, London

2024-07-02

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Cambridge, Leeds, London, Newcastle upon Tyne

2024-06-29

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

NCT06496178Head and Neck Squamous Cell Carcinoma

DrugPetosemtamab

Merus B.V.

Phase 3

621

Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne

2024-06-25

Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

NCT07491172Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder

CRISPR Therapeutics AG

Phase 1

Cambridge, London

2024-06-21

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Birmingham, Boston, Cambridge, Cardiff, Edinburgh, Gloucester, Harrogate, Leicester

2024-06-03

Recruiting

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277Obesity, Weight Gain

DrugTirzepatide

Eli Lilly and Company

Phase 3

300

Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield

2024-06-03

Recruiting

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464Prader-Willi Syndrome

DrugPitolisant

Harmony Biosciences Management, Inc.

Phase 3

134

Cambridge, Hull, Dundee, Edinburgh

2024-05-28

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386Prostatic Neoplasms, Castration-Resistant

DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Taxotere

Merck Sharp & Dohme LLC

Phase 1/2

220

Cambridge, Glasgow, Preston, London, Birmingham

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Cambridge, Edinburgh, London, Nottingham, Leeds, Manchester

2024-05-19

Recruiting

Hearing and Structure Preservation Via ECochG

NCT06268340Hearing Loss, Sensorineural, Severe-to-profound Hearing Loss

Advanced Bionics AG

Not applicable

102

Cambridge

2024-05-15

Active, closed

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)

DrugsKeytruda·Pembrolizumab

Inhibrx Biosciences, Inc

Phase 2/3

410

Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich

2024-05-14

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

450

Cambridge, Dundee, London, Manchester

2024-05-03

Recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease

DrugVERVE-102

Verve Therapeutics, Inc.

Phase 1

Birmingham, Cambridge, Edinburgh, London, Manchester, Nottingham

2024-04-30

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

Cambridge, Guildford, London, Manchester

2024-04-22

By invitation

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

NCT06262399Hereditary Angioedema

Intellia Therapeutics

Observational

100

Cambridge

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

Airdrie, Barnet, Cambridge, Clydebank, Exeter, Harefield, Hastings, High Wycombe

2024-04-12

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

Cambridge, Glasgow, London, Edinburgh, Manchester

2024-04-10

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Cambridge, Northwood, London, Oxford, Newcastle upon Tyne

2024-04-03

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Birmingham, Cambridge, Cardiff, Leeds, London, Manchester, Metropolitan Borough of Wirral, Southampton

2024-04-01

Active, closed

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

NCT06254950Ulcerative Colitis

DrugZasocitinib

Takeda

Phase 2

213

London, Belfast, Cambridge

2024-03-29

Active, closed

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376Immunoglobulin A Nephropathy, IgAN

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

584

Cambridge, Doncaster, Leicester, London, Manchester, Reading, Stevenage

2024-03-29

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Bristol, Cambridge, Dundee, Glasgow, Harrow, Hounslow, Leicester, Liverpool

2024-03-29

Recruiting

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

DrugsFT819·Fludara·Bendamustine·Cytoxan

Fate Therapeutics

Phase 1

244

Manchester, Cambridge, London

2024-03-28

Active, closed

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934Ulcerative Colitis

Gilead Sciences

Phase 2

228

Bristol, Bury, Cambridge, Cardiff, London, North Shields

2024-03-27

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Cambridge, Glasgow, London, Oxford

2024-03-23

Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121Pulmonary Sarcoidosis

Molecure S.A.

Phase 2

Birmingham, Cambridge, Edinburgh, London

2024-03-21

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Glasgow, Cambridge, Edinburgh, Leicester, London, Manchester, Sutton

2024-03-18

Recruiting

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461Crohn's Disease

DrugZasocitinib

Takeda

Phase 2

268

Cambridge, London, Belfast

2024-03-05

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Cambridge, London, Manchester, Oxford, Taunton

2024-03-04

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

Cambridge, Coventry, London, Nottingham

2024-02-26

Recruiting

A Global Prospective Observational Registry of Patients With Pompe Disease

NCT06121011Pompe Disease

DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa

Amicus Therapeutics

Observational

500

Birmingham, Cambridge, Cardiff, London, Manchester, Salford

2024-02-16

Recruiting

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

NCT06484868Partial Lipodystrophy

DrugMetreleptin

Amryt Pharma

Phase 4

Cambridge

2024-02-08

Active, closed

Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus

NCT06333483Systemic Lupus Erythematosus

DrugObecabtagene autoleucel

Autolus Limited

Phase 1

Cambridge, London, Manchester

2024-02-02

Active, closed

A Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease

NCT06150820Pompe Disease (Late-onset)

Astellas Gene Therapies

Not applicable

119

Cambridge, Newcastle upon Tyne, Salford

2024-02-01

Active, closed

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

NCT06237335Cystic Fibrosis

DrugIvacaftor

ReCode Therapeutics

Phase 2

128

Birmingham, Cambridge, Leeds, London, Nottingham, Southampton

2024-02-01

Active, closed

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596Metastatic Urothelial Cancer

DrugsZelenectide pevedotin·Avelumab·Gemcitabine·Cisplatin

BicycleTx Limited

Phase 2

375

Bristol, Cambridge, London, Plymouth, Sutton

2024-01-24

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease

DrugsGedatolisib·Darolutamide

Celcuity Inc

Phase 1/2

Cambridge, Southampton, Sutton

2024-01-01

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Cambridge, Truro, Glasgow, London, Manchester

2023-12-31

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Cambridge, Gloucester, Lincoln, Boston, London, Gwent, Windsor, Manchester

2023-12-31

Active, closed

Affera Global Registry

NCT06026345Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

540

Cambridge, London

2023-12-22

Active, closed

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome

NS Pharma, Inc.

Phase 2

Edgbaston, Cambridge, Reading

2023-12-20

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford

2023-12-18

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Aberdeen, Cambridge, Hampshire, Leeds, London, Manchester, Metropolitan Borough of Wirral, Northwood

2023-12-14

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham

2023-12-11

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Cambridge, Dundee, Birmingham, Glasgow, Leicester, Harrow

2023-12-11

Active, closed

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972Ulcerative Colitis

Gilead Sciences

Phase 2

176

Bury, Cambridge, London, Norwich, Southampton

2023-12-05

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Cambridge, Leeds, London, Manchester

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Cambridge, Edgbaston, Glasgow, Scotland, London, Manchester, Sutton

2023-12-04

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

NCT06127043Ulcerative Colitis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

132

Belfast, Cambridge, Liverpool, London, Runcorn, Shrewsbury, York

2023-12-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Birmingham, Cambridge, Liverpool, London, Newcastle upon Tyne

2023-12-01

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

NCT06166056Bronchiectasis

Chiesi Farmaceutici S.p.A.

Phase 1/2

Cambridge, Dundee, Edinburgh, Glasgow, Leeds, London, Manchester, Southampton

2023-11-29

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors

DrugsTecentriq·Atezolizumab

Genentech, Inc.

Phase 1

Cambridge, Leicester, London, Oxford, Sutton

2023-11-27

Active, closed

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06154837Pulmonary Disease, Chronic Obstructive

DrugGSK3862995B

GlaxoSmithKline

Phase 1

127

Barnsley, Blackpool, Cambridge, Cannock, London, Manchester, West Yorkshire

2023-11-27

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne

2023-11-21

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

289

High Wycombe, Cambridge, London, North Finchley, Birmingham, Dudley, Prescot, Stockport

2023-11-15

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton

2023-11-09

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease

DrugTreprostinil

United Therapeutics

Phase 3

698

Birmingham, Cambridge, Edinburgh, London, Manchester, Perth

2023-10-30

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Bristol, Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, West Midlands

2023-10-25

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter

2023-10-25

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

Liverpool, Belfast, Birmingham, Cambridge, London

2023-10-18

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Aberdeen, Burton-on-Trent, Cambridge, Derby, Guildford, Ipswich, Lancaster, Leeds

2023-10-05

Active, closed

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677Hereditary Angioedema

DrugNavenibart

Astria Therapeutics, Inc.

Phase 2

Cambridge, Leeds

2023-09-26

Active, closed

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

NCT06088290Leiomyosarcoma

DrugsLurbinectedin·Doxorubicin

PharmaMar

Phase 3

469

Birmingham, Cambridge, Liverpool, London, Manchester, Oxford

2023-09-21

Active, closed

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06052306Metastatic Castration-resistant Prostate Cancer

Bayer

Phase 1

232

Cambridge, London, Sutton

2023-09-20

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Cambridge, Edinburgh, Birmingham, London, Manchester

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough

2023-09-14

Recruiting

Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease

NCT06259019Coronary Artery Disease

PlaqueTec Ltd

Not applicable

300

Bournemouth, Bristol, Cambridge, Norwich

2023-09-14

Active, closed

Avacostar - (PASS)

NCT05897684ANCA-associated Vasculitis

Vifor Fresenius Medical Care Renal Pharma

Observational

507

Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry

2023-09-11

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

NCT06047171Glomerulonephritis Rapidly Progressive

DrugsCyclophosphamid·Rituximab

Alentis Therapeutics AG

Phase 2

Birmingham, Cambridge, Liverpool, London, Manchester, Preston

2023-09-07

Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal

AviadoBio Ltd

Phase 1/2

Cambridge, Cardiff, London

2023-08-30

By invitation

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

NCT05962398Hemophilia B

CSL Behring

Observational

London, Cambridge, Southampton

2023-08-30

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

Sutton, Barnet, Cambridge, Glasgow, Middlesbrough

2023-08-14

Active, closed

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

NCT05899673Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

Cambridge, Edinburgh

2023-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Cambridge, Leicester, London, Oxford, Salford

2023-08-08

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors

DrugsINCA33890·ADG126·Folfox·Cetuximab

Incyte Corporation

Phase 1

570

Cambridge, London, Manchester, Newcastle upon Tyne

2023-07-24

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester

2023-07-19

Active, closed

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430Hypertension

Mineralys Therapeutics Inc.

Phase 3

1,076

Newquay, Fowey, Glasgow, Chippenham, Cambridge, Carshalton, London, Plymouth

2023-07-14

Active, closed

CGM Use in Adults With Type 2 Diabetes on Basal Insulin

NCT05944432Diabetes Mellitus, Type 2

Abbott Diabetes Care

Not applicable

469

Ashton-under-Lyne, Bath, Birmingham, Cambridge, Darlington, Derby, Dundee, Harlow

2023-07-14

Recruiting

GEKO Venous Thromboembolism Prevention Study

NCT05476913Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism

Firstkind Ltd

Not applicable

1,200

Bury St Edmunds, Bath, Birmingham, Bournemouth, Bury, Cambridge, Canterbury, Chester

2023-07-06

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

DrugAstegolimab

Hoffmann-La Roche

Phase 3

2,000

Cambridge, London, Bellshill, Bradford, Cardiff, Chesterfield, Chorley, Cottingham

2023-06-28

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Birmingham, Cambridge, Exeter, Leicester, London, Middlesbrough, Torquay, Manchester

2023-06-28

Recruiting

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Regeneron Pharmaceuticals

Phase 1/2

Cambridge, London

2023-06-27

Active, closed

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

MeiraGTx, LLC

Phase 2

290

Cambridge, Cardiff, Dundee, Glasgow, Leeds, London, Nottingham, York

2023-06-13

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Cambridge, Leicester, London

2023-06-09

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Cambridge, Glasgow, Scotland, London, Sutton

2023-06-05

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Cambridge, Leicester, Manchester, Sutton

2023-05-02

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Cambridge, London, Manchester

2023-04-24

By invitation

An Observational Study of Patients With Moderate Parkinson's Disease

NCT05779475Parkinson Disease

Novo Nordisk A/S

Observational

Cambridge

2023-04-05

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Brighton, Burton-on-Trent, Cambridge, Derby, Edinburgh, Guildford, Ipswich, Keighley

2023-03-31

Active, closed

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

NCT05501873Atrial Fibrillation

Boston Scientific Corporation

Observational

1,173

Cambridge, Liverpool

2023-03-24

Recruiting

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971Alpha1-Antitrypsin Deficiency

DrugFazirsiran

Takeda

Phase 3

160

Cambridge, Edinburgh, London, Nottingham, Plymouth

2023-03-06

Active, closed

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551Huntington Disease

Hoffmann-La Roche

Phase 2

301

Birmingham, Cambridge, Leeds, London, Oxford, Southampton

2023-02-03

Active, closed

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

NCT05701774Prader-Willi Syndrome

Soleno Therapeutics, Inc.

Phase 3

Cambridge, Glasgow, Hull, London

2023-01-31

Active, closed

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304Ischemic Stroke, Systemic Embolism

AtriCure, Inc.

Not applicable

6,573

Sheffield, London, Middlesbrough, Wolverhampton, Cambridge

2023-01-25

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London

2023-01-23

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Cambridge, London, Bury, Harrow, Yeovil, Huddersfield

2023-01-16

Active, closed

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

NCT05526560Mitral Stenosis, Mitral Valve Insufficiency

Edwards Lifesciences

Observational

504

Cambridge, London

2023-01-11

By invitation

A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

NCT05768386Hemophilia A

BioMarin Pharmaceutical

Observational

172

Cambridge, Glasgow, London, Oxford, Southampton

2023-01-01

Active, closed

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NCT05687266NSCLC

DrugsDato-DXd·Durvalumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 3

1,350

Aberdeen, Cambridge, Cardiff, Cheltenham, Edinburgh, London, Manchester, Middlesbrough

2022-12-29

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Cambridge, Cornwell, Exeter, London, Motherwell, Oxford, Southampton

2022-12-23

Recruiting

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

NCT05669950Congenital Adrenal Hyperplasia

DrugLu AG13909

H. Lundbeck A/S

Phase 1/2

Birmingham, Cambridge, London

2022-12-19

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton

2022-12-19

Recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229Primary Mitochondrial Disease

DrugNapazimone

Pharming Technologies B.V.

Phase 2

180

Cambridge, London, Newcastle

2022-12-13

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne

2022-11-28

Active, closed

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843Colitis Ulcerative

Sanofi

Phase 2

187

Cambridge, London, Warrington

2022-11-25

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Birmingham, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Leeds, Liverpool

2022-11-08

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Orpington, Blackpool, Bristol, Cambridge, Chester, Chippenham, Coventry, Liverpool

2022-11-01

Active, closed

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

NCT05409976Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis

W.L.Gore & Associates

Not applicable

136

Cambridge, London

2022-10-25

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester

2022-10-24

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton

2022-09-22

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Cambridge, Truro, Airdrie, London, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford

2022-09-19

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford

2022-09-08

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Cambridge, Dundee, London, Manchester

2022-09-06

Active, closed

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222NASH, Cirrhosis, Liver

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

845

Birmingham, Cambridge, London

2022-08-26

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Cambridge, Chelsea, Manchester, Northwood

2022-08-11

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289Lupus Nephritis

DrugIptacopan

Novartis Pharmaceuticals

Phase 2

240

Cambridge, Leicester

2022-08-10

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Cambridge, Hull, Liverpool, London, Manchester, Tooting

2022-08-10

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton

2022-07-22

Active, closed

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934Eosinophilic Granulomatosis With Polyangiitis

DrugsDepemokimab·Mepolizumab

GlaxoSmithKline

Phase 3

163

Birmingham, Cambridge, London

2022-07-14

Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease

AC Immune SA

Phase 1/2

304

Cambridge, Liverpool, London, Oxford, Warrington

2022-06-21

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189Non-Small Cell Lung Cancer

DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib

BioNTech SE

Phase 1

320

Cambridge, Cardiff, Liverpool, London, Newcastle upon Tyne

2022-06-17

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142Clear Cell Renal Cell Carcinoma

Xencor, Inc.

Phase 1

307

Cambridge

2022-06-13

Active, closed

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

NCT05367440Metastatic Prostate Cancer

DrugsSaruparib·Zytiga·Apalutamide·Xtandi

AstraZeneca

Phase 1/2

174

Cambridge, Glasgow, Manchester, Plymouth

2022-06-02

Recruiting

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

NCT04879329Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Pembrolizumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

372

Glasgow, Cambridge, London, Manchester, Merseyside

2022-05-03

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer

DrugsBezuclastinib·Sunitinib·Midazolam

Cogent Biosciences, Inc.

Phase 3

482

Cambridge, Glasgow, London, Manchester, Sheffield

2022-04-14

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton

2022-03-25

Active, closed

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646Immunoglobulin A Nephropathy

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

530

Cambridge, Gloucester, Leicester, London, Salford, Swansea

2022-03-15

Active, closed

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773Fabry Disease

DrugVenglustat

Sanofi

Phase 3

122

Cambridge, London, Salford

2022-03-11

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780Sickle Cell Disease

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 2/3

286

London, Cambridge, Manchester

2022-02-11

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845Primary Immune Thrombocytopenia

Pfizer

Phase 2

Cambridge, Plymouth, Truro, London

2022-02-02

Active, closed

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases

Quell Therapeutics Limited

Phase 1/2

Birmingham, Cambridge, London

2022-01-21

Recruiting

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

NCT05102019Refractory Angina

Shockwave Medical, Inc.

Not applicable

380

Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool

2022-01-04

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

194

Cambridge, Manchester, London

2021-12-20

Active, closed

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

NCT05097287Asthma

DrugDupilumab

Sanofi

Phase 4

1,339

Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield

2021-12-16

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Cambridge, London, Middlesex

2021-12-14

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

643

East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff

2021-12-13

Active, closed

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830Hereditary Angioedema

Intellia Therapeutics

Phase 1/2

Cambridge

2021-12-10

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough

2021-11-07

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296Systemic Lupus Erythematosus

DrugsAcetaminophen/paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

303

Cambridge, Leeds, London, Manchester

2021-10-26

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Tecentriq

Hoffmann-La Roche

Phase 1

542

Cambridge, Cardiff, London, Manchester, Sutton

2021-10-22

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Cambridge, Cardiff, London

2021-10-18

Active, closed

A Long-term Extension Study of Ustekinumab in Pediatric Participants

NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic

DrugUstekinumab

Janssen Research & Development, LLC

Phase 3

159

Birmingham, Cambridge, London, Sheffield, Southampton

2021-10-18

Active, closed

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696Systemic Lupus Erythematosus

Beeline Medicines Corporation

Phase 2

248

Cambridge, Bradford, Manchester

2021-10-11

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma

DrugPaclitaxel

Nurix Therapeutics, Inc.

Phase 1

345

Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford

2021-09-29

Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

540

Newcastle upon Tyne, Cambridge, Leicester, London, Salford

2021-09-20

Active, closed

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282Desmoid, Desmoid Tumor

Immunome, Inc.

Phase 2/3

198

Edinburgh, Cambridge, London, Manchester

2021-09-01

Active, closed

Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866Fabry Disease, Fabry Disease, Cardiac Variant

Sangamo Therapeutics

Observational

Cambridge, London

2021-08-16

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Bradford, Cambridge, London, Londonderry, North Shields, Portadown, Sheffield, Stevenage

2021-08-14

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Cambridge, London, Glasgow

2021-08-12

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

Blackpool, Cambridge, London, Manchester, Newport, Nottingham, Portsmouth, Reading

2021-06-30

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London

2021-06-24

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Sutton, Belfast, Cambridge, Glasgow, London, Middlesbrough

2021-06-09

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester

2021-05-21

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 3

815

Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield

2021-05-12

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Blackpool, Brighton, Cambridge, Cheltenham, London, Manchester, Northwood, Preston

2021-05-04

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton

2021-05-03

Active, closed

Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity

NCT04769037Diabetes Mellitus, Type 1

Helmholtz Zentrum München

Not applicable

1,149

Cambridge, Newcastle

2021-04-22

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

1,688

Cambridge, London, Northwood

2021-04-14

Active, closed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

430

Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford

2021-04-09

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Cambridge, Colchester, Leeds, Nottingham, Surrey

2021-01-28

Active, closed

Comparing UroLift Experience Against Rezūm

NCT04338776Benign Prostatic Hyperplasia

NeoTract, Inc.

Not applicable

120

Frimley, Norwich, Cambridge

2021-01-22

Active, closed

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer

DrugPembrolizumab

BioNTech SE

Phase 2/3

358

Aberdeen, Belfast, Birmingham, Cambridge, Cardiff, Glasgow, Leeds, Liverpool

2021-01-07

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308Primary Sclerosing Cholangitis

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

182

London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne

2020-12-18

Active, closed

PARADIGM: Amplatzer Valvular Plug for PVL Closure

NCT04489823Paravalvular Aortic Regurgitation

Abbott Medical Devices

Not applicable

200

Edinburgh, Brighton, Cambridge

2020-12-01

Active, closed

Non-ischemic Preservation of the Donor Heart in Heart Transplantation

NCT03991923Heart Transplantation

XVIVO Perfusion

Not applicable

230

Newcastle, Birmingham, Cambridge

2020-11-25

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey

2020-11-17

Active, closed

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer

DrugsSaruparib·Camizestrant·Dato-DXd·Trastuzumab deruxtecan

AstraZeneca

Phase 1/2

702

Cambridge, Manchester, Oxford, Sutton

2020-11-12

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham

2020-09-30

Active, closed

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665Primary Biliary Cirrhosis

DrugElafibranor

Ipsen

Phase 3

161

Newcastle upon Tyne, Belfast, Camberley, Cambridge, Hull, London, Nottingham, Plymouth

2020-09-24

Active, closed

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477Lupus Nephritis

DrugsDiphenhydramine·Acetaminophen·Methylprednisolone·Obinutuzumab

Hoffmann-La Roche

Phase 3

271

Cambridge

2020-08-10

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood

2020-07-24

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Cambridge, Guildford, Manchester, Plymouth, Sutton, Whitchurch

2020-07-13

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Cambridge, London, Cardiff

2020-06-22

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Cambridge, Dundee, London, Manchester, Sutton

2020-06-03

Active, closed

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

NCT04404660Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

DrugAUTO1

Autolus Limited

Phase 1/2

153

Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol

2020-06-03

Active, closed

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750Carcinoma, Renal Cell

DrugsBelzutifan·Everolimus

Merck Sharp & Dohme LLC

Phase 3

755

Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester

2020-02-27

Active, closed

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

NCT04170153Metastatic or Locally Advanced Unresectable Solid Tumors

DrugsTuvusertib·Niraparib

EMD Serono Research & Development Institute, Inc.

Phase 1

161

Cambridge, Manchester, Newcastle upon Tyne, Sutton

2019-12-20

Active, closed

LAM561 With RT and TMZ for Adults With Glioblastoma

NCT04250922Primary Glioblastoma, Glioblastoma Multiforme

DrugLAM561

Laminar Pharmaceuticals

Phase 2/3

144

Newcastle, Birmingham, Cambridge, London

2019-12-01

Active, closed

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer

DrugsNuzefatide pevedotin·Opdivo·Nivolumab

BicycleTx Limited

Phase 1/2

288

London, Manchester, Cambridge, Leeds, Newcastle upon Tyne

2019-11-07

Active, closed

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348Eosinophilic Granulomatous Vasculitis

DrugsBenralizumab·Mepolizumab

AstraZeneca

Phase 3

140

Cambridge, Leicester, London, Portsmouth

2019-10-29

Active, closed

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

NCT04088409Uveitis

DrugsBaricitinib·Adalimumab

Eli Lilly and Company

Phase 3

Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield

2019-10-16

Active, closed

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300Asthma

DrugBenralizumab

AstraZeneca

Phase 4

Cambridge, Headington, Leicester, Liverpool, London, Wythenshawe

2019-10-08

Active, closed

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

DrugXeomin

Merz Pharmaceuticals GmbH

Phase 3

603

Cambridge, Exeter, Liverpool

2019-09-16

Active, closed

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV

DrugsDNA vaccine·ImmunoBody

Scancell Ltd

Phase 2

173

Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford

2019-08-19

Active, closed

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

NCT03814746Sickle Cell Disease (SCD)

DrugCrizanlizumab

Novartis Pharmaceuticals

Phase 3

254

Sheffield, Cambridge, London

2019-07-26

Active, closed

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

NCT03981796Neoplasms

DrugsNiraparib·Dostarlimab·Paclitaxel·Carboplatin

Tesaro, Inc.

Phase 3

785

Brighton, Cambridge, London, Truro

2019-07-18

Active, closed

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486Non-Small Cell Lung Cancer

DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib

AstraZeneca

Phase 3

587

Cambridge, Leicester, Liverpool, Maidstone, Manchester

2019-07-02

Active, closed

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219Renal Cell Carcinoma

DrugsCabozantinib·Yervoy·Ipilimumab·Opdivo

Exelixis

Phase 3

855

Cambridge, Glasgow, London, Manchester

2019-06-25

Active, closed

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)

OHB Neonatology Ltd.

Phase 2

295

Norwich, Chertsey, Cambridge, Coventry, Liverpool, London, Manchester

2019-05-09

Active, closed

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

NCT03875235Biliary Tract Neoplasms

DrugDurvalumab

AstraZeneca

Phase 3

810

Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield

2019-04-16

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Birmingham, Cambridge, Chorley, Hardwick, Liverpool, London, Manchester, Newcastle upon Tyne

2019-03-28

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab

Acerta Pharma BV

Phase 3

984

Cambridge, Canterbury, Wolverhampton

2019-02-25

Active, closed

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

NCT03742102Triple Negative Breast Neoplasms

DrugsOleclumab·Capivasertib·Dato-DXd·Trastuzumab deruxtecan

AstraZeneca

Phase 1/2

243

Cambridge, London, Manchester, Oxford

2018-12-21

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Cambridge, Cottingham-Hull, London, Sheffield

2018-12-17

Active, closed

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850Immunoglobulin A Nephropathy

DrugsSparsentan·Irbesartan·Dapagliflozin

Travere Therapeutics, Inc.

Phase 3

406

Reading, Cambridge, Middlesbrough, Derby, Brighton, London, Manchester, Salford

2018-12-11

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

DrugLutathera

Advanced Accelerator Applications

Observational

1,014

Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield

2018-11-28

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

DrugsPomalidomide·Venetoclax·Dexamethasone

AbbVie

Phase 3

265

Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth

2018-10-22

Active, closed

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

NCT03616587ER+ HER2- Advanced Breast Cancer

DrugCamizestrant

AstraZeneca

Phase 1

396

Cambridge, Leeds, London, Manchester, Sutton

2018-10-11

Active, closed

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

NCT03671018B-cell Non-Hodgkin Lymphoma

DrugsMosunetuzumab·Polatuzumab Vedotin·Tocilizumab·Rituximab

Hoffmann-La Roche

Phase 1/2

422

Cambridge, Plymouth

2018-09-25

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Cambridge, London, Sutton, Manchester

2018-09-12

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne

2018-08-28

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston

2018-08-21

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester

2018-06-21

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

NCT03755791Hepatocellular Carcinoma

DrugsSorafenib·Cabozantinib·Tecentriq·Atezolizumab

Exelixis

Phase 3

837

Bristol, Cambridge, London, Manchester, Belfast

2018-06-10

Active, closed

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed

DrugsRucaparib·Opdivo·Nivolumab

pharmaand GmbH

Phase 3

1,097

Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds

2018-05-14

Active, closed

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

NCT03401788VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation

DrugBelzutifan

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

Cambridge

2018-05-02

Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer

DrugPetosemtamab

Merus B.V.

Phase 1/2

560

Cambridge, London

2018-05-02

Active, closed

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell

DrugsChlorambucil·Ibrutinib·Obinutuzumab·Venetoclax

Janssen Research & Development, LLC

Phase 3

211

Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield

2018-04-17

Active, closed

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411Crohn's Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab

Janssen Research & Development, LLC

Phase 2/3

1,409

Barnsley, Cambridge, London

2018-04-13

Active, closed

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

NCT03105102Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,336

Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford

2018-04-09

Active, closed

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)

DrugAZD1390

AstraZeneca

Phase 1

159

Cambridge, Glasgow, Leeds

2018-04-02

Active, closed

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsVenclyxto·Bendamustine·Venclexta·Zanubrutinib

BeiGene

Phase 3

590

Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone

2017-10-31

Recruiting

Registry for Patients With X-Linked Hypophosphatemia

NCT03193476X-Linked Hypophosphatemia

Kyowa Kirin Pharmaceutical Development Ltd

Observational

1,489

Belfast, Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Glasgow, Inverness

2017-09-12

Active, closed

BioVentrix Revivent TC™ System Clinical Study

NCT02931240Ventricular Dysfunction, Left

BioVentrix

Not applicable

126

Cambridge, Newcastle upon Tyne

2017-08-29

Active, closed

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

NCT02962414Tuberous Sclerosis Complex

DrugEverolimus

Novartis Pharmaceuticals

Phase 3

206

Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield

2017-08-23

Active, closed

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318Chronic Lymphocytic Leukemia

DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab

Acerta Pharma BV

Phase 3

310

Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton

2017-02-02

Active, closed

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

NCT02843035Gaucher Disease Type 1, Gaucher Disease Type 3

DrugsImiglucerase·Venglustat

Genzyme, a Sanofi Company

Phase 2

Cambridge, Salford

2017-01-04

Active, closed

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

NCT02960022Prostate Cancer

DrugsLeuprolide Acetate·Xtandi·Abiraterone acetate·Enzalutamide

Astellas Pharma Global Development, Inc.

Phase 2

900

Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester

2016-12-22

Recruiting

MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674Generalised Lipodystrophy, Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Observational

100

Cambridge

2016-10-11

Active, closed

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT02734004Ovarian, Breast, SCLC, Gastric Cancers

DrugsAvastin·Olaparib·Durvalumab·Bevacizumab

AstraZeneca

Phase 1/2

264

Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton

2016-03-17

Active, closed

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms

DrugEntrectinib

Hoffmann-La Roche

Phase 2

534

Cambridge, London, Manchester

2015-11-19

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield

2015-11-02

Active, closed

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696Chronic Lymphocytic Leukemia

DrugsIbrutinib·Acalabrutinib

Acerta Pharma BV

Phase 3

533

Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester

2015-07-28

Active, closed

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681Chronic Lymphocytic Leukemia

DrugsChlorambucil·Acalabrutinib·Obinutuzumab

Acerta Pharma BV

Phase 3

535

Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro

2015-06-26

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Bebbington, Cambridge, Manchester, Sutton

2014-11-06

Active, closed

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02227251Diffuse Large B-cell Lymphoma

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

244

Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London

2014-11

Active, closed

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

DrugsSaruparib·Olaparib·Durvalumab·Carboplatin

AstraZeneca

Phase 1

358

Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington

2014-10-31

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh

2014-04-22

Active, closed

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

NCT01946204Prostatic Neoplasms

DrugApalutamide

Aragon Pharmaceuticals, Inc.

Phase 3

1,207

Blackburn, Cambridge, Cardiff, Dundee, Glasgow, Guildford, Leeds, London

2013-10-14

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

DrugOlaparib

AstraZeneca

Phase 3

327

Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton

2013-09-03

Active, closed

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation

DrugOlaparib

AstraZeneca

Phase 3

450

Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton

2013-08-26

Recruiting

Lysosomal Acid Lipase (LAL) Deficiency Registry

NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2

Alexion Pharmaceuticals, Inc.

Observational

300

Cambridge, London, Manchester, Salford, Birmingham

2013-05-30

Recruiting

Pompe Disease Registry Protocol

NCT00231400Glycogen Storage Disease Type II, Pompe Disease

Genzyme, a Sanofi Company

Observational

2,000

Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne

2004-09-15

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

Cambridge, Birmingham, London, Salford, Belfast, Manchester

2001-07-31

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Genzyme, a Sanofi Company

Observational

12,000

Cambridge, Birmingham, London, Salford, Manchester

1991-04-01

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/cambridge

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 425 of those studies with a site in Cambridge.

How many clinical trials are recruiting in Cambridge?

208 of the 425 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 6 have not yet opened recruitment, 201 are active but closed to new participants, and 10 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cambridge), 425 studies
Phase	Studies	Recruiting	Share
Phase 3	211	100	49.6%
Phase 2	83	38	19.5%
Phase 1	35	20	8.2%
Phase 1/2	33	21	7.8%
Observational	24	12	5.6%
Not applicable	19	6	4.5%
Phase 2/3	13	7	3.1%
Phase 4	7	4	1.6%

Most active sponsors

Lead sponsors with the most studies (Cambridge)
Lead sponsor	Studies	Recruiting
AstraZeneca	65	30
Merck Sharp & Dohme LLC	28	16
Janssen Research & Development, LLC	16	9
Hoffmann-La Roche	15	3
AbbVie	13	5
Novartis Pharmaceuticals	12	5
GlaxoSmithKline	10	6
Sanofi	9	4
Bristol-Myers Squibb	8	5
Eli Lilly and Company	7	4

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.